MX2021007468A - Compuestos que participan en la union cooperativa y usos de los mismos. - Google Patents

Compuestos que participan en la union cooperativa y usos de los mismos.

Info

Publication number
MX2021007468A
MX2021007468A MX2021007468A MX2021007468A MX2021007468A MX 2021007468 A MX2021007468 A MX 2021007468A MX 2021007468 A MX2021007468 A MX 2021007468A MX 2021007468 A MX2021007468 A MX 2021007468A MX 2021007468 A MX2021007468 A MX 2021007468A
Authority
MX
Mexico
Prior art keywords
compounds
participate
cooperative binding
ras
cancers
Prior art date
Application number
MX2021007468A
Other languages
English (en)
Inventor
Ning Yin
Anna Kohlmann
Jae Young Ahn
Meizhong Jin
Nicholas Perl
Elena S Koltun
Mark Joseph Mulvihill
Jason T Lowe
Adrian L Gill
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2021007468A publication Critical patent/MX2021007468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a compuestos macrocíclicos, solos y en combinación con otros agentes terapéuticos, así como composiciones farmacéuticas y complejos de proteínas de las mismas, capaces de modular los procesos biológicos incluyendo la inhibición de RAS y RAS-RAF, y sus usos en el tratamiento de cánceres.
MX2021007468A 2018-12-21 2019-12-20 Compuestos que participan en la union cooperativa y usos de los mismos. MX2021007468A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862783816P 2018-12-21 2018-12-21
US201962894493P 2019-08-30 2019-08-30
US201962930489P 2019-11-04 2019-11-04
PCT/US2019/068100 WO2020132597A1 (en) 2018-12-21 2019-12-20 Compounds that participate in cooperative binding and uses thereof

Publications (1)

Publication Number Publication Date
MX2021007468A true MX2021007468A (es) 2021-08-05

Family

ID=71099011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007468A MX2021007468A (es) 2018-12-21 2019-12-20 Compuestos que participan en la union cooperativa y usos de los mismos.

Country Status (13)

Country Link
US (1) US20200197391A1 (es)
EP (1) EP3897644A4 (es)
JP (1) JP2022520154A (es)
KR (1) KR20210116479A (es)
CN (1) CN113498342A (es)
AU (1) AU2019401466A1 (es)
BR (1) BR112021012057A2 (es)
CA (1) CA3123869A1 (es)
IL (1) IL284210A (es)
MX (1) MX2021007468A (es)
SG (1) SG11202106605VA (es)
TW (1) TW202039509A (es)
WO (1) WO2020132597A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
RU2020123241A (ru) 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
EP4054719A1 (en) * 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CA3159559A1 (en) * 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
US20210322405A1 (en) * 2020-04-15 2021-10-21 Washington University Compositions and methods for treating cancer
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
CA3202770A1 (en) * 2020-12-17 2022-06-23 Blossomhill Therapeutics, Inc. Macrocycles and their use
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
CN117715658A (zh) 2021-05-25 2024-03-15 锐新医药公司 抑制ras的方法
US20220395507A1 (en) * 2021-05-27 2022-12-15 Mirati Therapeutics, Inc. Combination therapies
WO2023015559A1 (en) * 2021-08-13 2023-02-16 Nutshell Biotech (Shanghai) Co., Ltd. Macrocycle compounds as inhibitors of ras
AR126854A1 (es) 2021-08-27 2023-11-22 Hoffmann La Roche Compuestos macrocíclicos para el tratamiento de cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
TW202400607A (zh) * 2022-04-25 2024-01-01 美商翰森生物有限責任公司 環狀化合物、製備方法及其醫藥用途
WO2023232776A1 (en) 2022-06-01 2023-12-07 F. Hoffmann-La Roche Ag Haloindole macrocyclic compounds for the treatment of cancer
WO2023240263A1 (en) * 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117903169A (zh) * 2022-09-19 2024-04-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
WO2024067857A1 (zh) * 2022-09-29 2024-04-04 南京明德新药研发有限公司 大环衍生物及其应用
CN116284045A (zh) * 2023-05-18 2023-06-23 西南交通大学 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
CN116570599B (zh) * 2023-07-04 2023-10-20 四川大学华西医院 Vs6766联合ly3009120的应用及药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
EP2710018B8 (en) * 2011-05-19 2022-02-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae

Also Published As

Publication number Publication date
CN113498342A (zh) 2021-10-12
WO2020132597A8 (en) 2020-07-16
TW202039509A (zh) 2020-11-01
AU2019401466A1 (en) 2021-07-01
WO2020132597A1 (en) 2020-06-25
KR20210116479A (ko) 2021-09-27
EP3897644A4 (en) 2022-09-07
SG11202106605VA (en) 2021-07-29
CA3123869A1 (en) 2020-06-25
EP3897644A1 (en) 2021-10-27
US20200197391A1 (en) 2020-06-25
JP2022520154A (ja) 2022-03-29
BR112021012057A2 (pt) 2021-10-19
IL284210A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
CR20220240A (es) Inhibidores de ras
CR20220243A (es) Inhibidores de ras
CR20220241A (es) Inhibidores de ras
MX2020001513A (es) Agentes de union a clec9a y su uso.
CR20230165A (es) Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP4276114A3 (en) Cd20 binding single domain antibodies
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
AU2018278311A1 (en) IRE1 small molecule inhibitors
SG10201902664RA (en) Combination therapy for treating cancer
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CR20230570A (es) Inhibidores de ras
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
MX2018015172A (es) Metodos para tratar cancer pancreatico.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.